{
    "nct_id": "NCT06614192",
    "official_title": "AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Life expectancy >= 12 weeks per investigator assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period prior to the first dose of the study drug.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic regimen containing c-MET targeting antibody or Antibody Drug Conjugate (ADC).\n* History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.\n* Active infection as noted in the protocol.",
    "miscellaneous_criteria": ""
}